Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Cerus Corporation (NASDAQ:CERS) Stock Price

News coverage about Cerus Corporation (NASDAQ:CERS) has trended somewhat positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerus Corporation earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.474910133559 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

A number of equities research analysts recently commented on CERS shares. Cantor Fitzgerald set a $7.00 price target on shares of Cerus Corporation and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Zacks Investment Research raised shares of Cerus Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. BTIG Research reissued a “buy” rating and set a $5.00 target price on shares of Cerus Corporation in a report on Sunday, May 28th. ValuEngine cut shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Finally, BidaskClub raised shares of Cerus Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $7.25.

Cerus Corporation (CERS) traded down 0.79% during mid-day trading on Friday, reaching $2.50. 361,299 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $2.36 and its 200 day moving average price is $3.31. Cerus Corporation has a one year low of $1.93 and a one year high of $7.19. The firm’s market cap is $272.84 million.

Cerus Corporation (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The business had revenue of $9.53 million during the quarter, compared to analysts’ expectations of $9.14 million. During the same period last year, the company posted ($0.18) EPS. The business’s revenue was up 3.0% on a year-over-year basis. On average, equities analysts forecast that Cerus Corporation will post ($0.68) EPS for the current year.

In other Cerus Corporation news, insider Laurence M. Corash acquired 92,796 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $2.45 per share, with a total value of $227,350.20. Following the purchase, the insider now directly owns 1,375,711 shares of the company’s stock, valued at approximately $3,370,491.95. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 7.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was first posted by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/cerus-nasdaqcers-earns-daily-news-sentiment-score-of-0-08-updated.html.

About Cerus Corporation

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus Corporation (NASDAQ:CERS)

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply